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ABSTRACT: SGK3 is a PX domain containing protein kinase activated at
endosomes downstream of class 1 and 3 PI3K family members by growth factors
and oncogenic mutations. SGK3 plays a key role in mediating resistance of breast
cancer cells to class 1 PI3K or Akt inhibitors, by substituting for the loss of Akt
activity and restoring proliferative pathways such as mTORC1 signaling. It is
therefore critical to develop tools to potently target SGK3 and obstruct its role in
inhibitor resistance. Here, we describe the development of SGK3-PROTAC1, a
PROTAC conjugate of the 308-R SGK inhibitor with the VH032 VHL binding
ligand, targeting SGK3 for degradation. SGK3-PROTAC1 (0.3 μM) induced 50%
degradation of endogenous SGK3 within 2 h, with maximal 80% degradation
observed within 8 h, accompanied by a loss of phosphorylation of NDRG1, an
SGK3 substrate. SGK3-PROTAC1 did not degrade closely related SGK1 and
SGK2 isoforms that are nevertheless engaged and inhibited by 308-R. Proteomic
analysis revealed that SGK3 was the only cellular protein whose cellular levels were
signiﬁcantly reduced following treatment with SGK3-PROTAC1. Low doses of SGK3-PROTAC1 (0.1−0.3 μM) restored
sensitivity of SGK3 dependent ZR-75-1 and CAMA-1 breast cancer cells to Akt (AZD5363) and PI3K (GDC0941) inhibitors,
whereas the cis epimer analogue incapable of binding to the VHL E3 ligase had no impact. SGK3-PROTAC1 suppressed
proliferation of ZR-75-1 and CAMA-1 cancer cell lines treated with a PI3K inhibitor (GDC0941) more eﬀectively than could be
achieved by a conventional SGK isoform inhibitor (14H). This work underscores the beneﬁt of the PROTAC approach in
targeting protein kinase signaling pathways with greater eﬃcacy and selectivity than can be achieved with conventional
inhibitors. SGK3-PROTAC1 will be an important reagent to explore the roles of the SGK3 pathway.
The PI3K pathway orchestrates vital cellular processesincluding metabolism, insulin signaling, and protein
synthesis as well as proliferation and growth.1 Hyperactivating
mutations in components of the class I PI3K family (p110α,
p110β, p110γ, and p110δ) are harbored in the majority of
human cancers and drive proliferation and survival of tumors.2 A
key downstream component of the class 1 PI3K pathway are
isoforms of the serum and glucocorticoid-induced protein
kinases (SGK1, SGK2, and SGK3) that are activated by PDK1
and mTORC2.3−5 The kinase domains of SGK isoforms are
highly related to intensely studied Akt isoforms that are also
activated downstream of class 1 PI3K signaling via the PDK1
and mTORC2 kinases. SGK and Akt isoforms regulate cellular
processes by phosphorylating a myriad of overlapping substrates
at Ser/Thr residues lying within RXRXXT/S substrate
recognition motifs.6,7
SGK3 is the only isoform that possesses an N-terminal phox
homology (PX) domain which interacts with high aﬃnity and
speciﬁcity to PtdIns(3)P, generated by the class III PI3K
(hVPS34) at the endosome.8−10 Binding PtdIns(3)P promotes
the phosphorylation and activation of SGK3 by PDK1 and
mTORC2 kinases.9 In addition, SGK3 can also be activated
downstream of class 1 PI3K through a pathway involving
activation of mTORC2 and sequential dephosphorylation of
PtdIns(3,4,5)P3 to PtdIns(3)P.
8 In contrast, SGK1 and SGK2
isoforms lack a phosphoinositide binding domain and are
therefore activated in the cytosol downstream of class 1 PI3K
through its activation of mTORC2, triggering PDK1 phosphor-
ylation.4,11 Unlike SGK3, Akt isoforms possess an N-terminal
PtdIns(3,4,5)P3 binding PH domain. Activation of class 1 PI3K
generates PtdIns(3,4,5)P3 at the plasma membrane that in turn
promotes recruitment and phosphorylation of Akt isoforms by
PDK1 and mTORC2.
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Prolonged treatment of various ER+ breast cancer cell lines
with class 1 PI3K or Akt inhibitors leads to upregulation and
activation of SGK3 through the hVPS34 pathway.12 Under these
conditions, SGK3 substitutes for Akt by phosphorylating
substrates such as TSC2 to activate mTORC1.12 Moreover, a
combination of Akt and SGK protein kinase inhibitors induced a
more marked regression of BT-474 breast cancer cell-derived
tumors in a xenograft model than observed with Akt inhibitors
alone.12 These data support the notion of targeting SGK3 as a
therapeutic strategy for counteracting resistance to PI3K/Akt
inhibition in cancer treatment. A number of ATP competitive
inhibitors that target all SGK isoforms with similar aﬃnity have
been reported.13−15 Due to the high homology of their SGK
catalytic domains, it has not been possible to elaborate inhibitors
that display isoform speciﬁcity.16 These compounds could have
less toxicity for treating cancer resistance than inhibitors
targeting all isoforms.
Proteolysis targeting chimeras (PROTACs) are heterobifunc-
tional small molecules designed to induce rapid proteasome-
mediated degradation of a protein of interest.17 They consist of a
ligand that binds to the protein of interest, joined via a short
linker sequence to an E3 ligase recruitment moiety.18,19 A key
advantage of PROTACs is that they can be deployed at much
lower doses than conventional inhibitors due to their
substochiometric catalytical mode of action eﬃciently degrading
target proteins, minimizing side eﬀects.20−22 The PROTAC
approach reduces intracellular protein levels much more rapidly
than is achievable with genetic methodologies, which can
present other challenges such as lethality or genetic
compensation.23 Additionally, PROTACs can be used reversibly
and have been demonstrated to display exquisite isoform or
paralog speciﬁcity that is challenging to achieve by pan-selective
inhibitors.21,24−26 A range of PROTAC tool compounds has
recently been developed targeting protein kinases, for example,
against RIPK2,20 BCR-ABL,27,28 CDK9,29 and PTK2.30,31 As
Figure 1. Design and cellular activity of ﬁrst generation SGK3 PROTACs. (A) Structure of compound 14H, previously published by Sanoﬁ as an
inhibitor of SGK3. (B) Starting material for SGK PROTACs. PROTACs were derived from SGK inhibitors 308-R or 290-R linked to either VH032 or
pomalidomide to target the VHL or cereblon E3 ligases, respectively. (C) Structures of ﬁrst generation SGK PROTACs. SGK and E3 ligase targeting
motifs were joined by a 3xPEG linker to produce the PROTACs. (D) HEK293 cells were treated for 48 h with increasing concentrations of each
PROTAC compound from 0.1 nM to 10 μM. Cell lysates were subjected to immunoblot analysis with the indicated antibodies, and SGK3 protein
levels were quantiﬁed in Image Studio Lite software (Licor).
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recently reviewed by Ferguson and Gray, PROTACs can evade
issues with conventional chemical inhibitors in targeting
oncogenic kinases32 and allow targeting both kinase-dependent
and kinase-independent protein functions. Targeting of protein
kinases for degradation has also allowed for greater isoform
speciﬁcity, for example, the production of a CDK6-speciﬁc
PROTAC from a CDK4/6 inhibitor.33
In this study, we describe the optimization and character-
ization of an SGK3-speciﬁc PROTAC termed SGK3-PRO-
TAC1. This compound is a highly selective degrader, targeting
for degradation only SGK3 and not the related SGK1 or SGK2
isoform. SGK3-PROTAC1 induces proteasomal-mediated
degradation of SGK3 at submicromolar concentrations in a
panel of cancer cell lines rendering breast cancer cells more
sensitive to PI3K and Akt inhibitors. SGK3-PROTAC1
represents a novel chemical tool to better probe the biological
roles of the SGK3 protein kinase.
■ RESULTS AND DISCUSSION
Elaboration of DAT1, a First-Generation SGK3
PROTAC. As no cocrystal structure of the SGK1−3 inhibitors
has been disclosed, we inspected the structure−activity
relationship (SAR) of a series of structurally related SGK
inhibitors reported by Sanoﬁ13 (International Patent
WO2014140065), with the aim to identify strategies to
elaborate PROTACs. From this series, we have previously
characterized compound 14H as an inhibitor of SGK3 and
shown that inhibition of SGK3 kinase activity with this
compound can reduce PI3K-Akt inhibitor resistant cell
growth.12 However, this compound lacks isoform speciﬁcity
and also has some potency against S6K1. Inhibitor 14H
possesses an IC50 of 4 nM for SGK3, 10 nM for SGK1, and
76 nM for S6K1.12 A series of inhibitors that have a
pyrazolopyrimidine scaﬀold appeared to tolerate aliphatic and
cyclic substituents at position 4 of the pyrazolopyrimidine core,
suggesting that such a portion of the molecule could be solvent
exposed. Two SGK inhibitors, termed 290 and 308 (Figure 1B),
were judged particularly amenable for linker conjugation, as the
morpholine ring can be selectively N-alkylated by means of
reductive amination protocols. As the inhibitors described in the
patent were racemic, we synthesized both the R and S
enantiomers of these compounds and determined by kinase
screening that the R forms were marginally more potent (data
available at http://www.kinase-screen.mrc.ac.uk/kinase-
inhibitors). We determined that the IC50s of these compounds
for SGK1 and SGK3 were between 5 and 40 nM (Table 1). The
speciﬁcity of these compounds was proﬁled against 140 kinases
at a 1 μM concentration, revealing that they were relatively
selective (Table S1), with S6K1 being a key oﬀ target that was
inhibited more potently than SGK isoforms, with an IC50 of 1−
10 nM (Table 1).
For the ﬁrst generation of SGK PROTAC molecules, we
linked 290-R and 308-R to the well characterized VHL ligand
VH03234,35 and to the cereblon ligand pomalidomide.36 A
medium length linker composed of three PEG units was used in
the ﬁrst instance (Figure 1B and C). We next tested whether the
resulting compounds reduced endogenous SGK isoform or
S6K1 expression when administered to HEK293 cells for 48 h at
concentrations of up to 10 μM (Figure 1D). After 48 h of
PROTAC treatment, cell lysates were analyzed by immunoblot
analysis, and protein expression under each condition was
quantiﬁed relative to the DMSO-only control. Only one of the
four compounds, in which 308-R was conjugated to the VHL
ligand VH032 (termed DAT1), markedly reduced SGK3
expression. Levels of SGK1, SGK2, or S6K1 were not
signiﬁcantly impacted (Figure 1D). DAT1 reduced SGK3
expression by 60% at 1 μM and 75% at 10 μM after 48 h (Figure
1D). Treatment of 1 μM DAT1 maximally reduced SGK3
expression by 16 h (Figure S1A). A dose response analysis
revealed that 2 μM DAT1 maximally reduced SGK3 expression
at an 8 h time point (Figure S1B). As expected, inhibition of
CUL2 neddylation by means of the inhibitor MLN4924 (3 μM)
or proteasome inhibition (MG132, 50 μM) blocked DAT1-
induced degradation of SGK3 (Figure S1C). This suggests that
DAT1-mediated degradation of SGK3 is neddylation and
proteasome dependent.
Conjugation of 308-R to VH032 or pomalidomide markedly
decreased the inhibitory activity for SGK isoforms and S6K1 in
biochemical kinase assays (5 nM to 440 nM for SGK3 and 1 nM
to 160 nM for S6K1; Table 1).We found no correlation between
the potency of PROTACs for inhibiting SGK3 and the ability to
induce degradation of SGK3 in cells. For example, DAT2, which
does not impact SGK3 protein levels in HEK293 cells, inhibited
SGK1 and SGK3 2−4-fold more potently than DAT1.
Elaboration of DAT8 (SGK3-PROTAC1), a Second
Generation SGK3 PROTAC. We next generated further
analogues of DAT1 by shortening the linker length from three
to two PEG units (DAT5) or extending the linker length to four
and ﬁve PEG units (DAT6,7; Figure 2A). The ability of each of
these compounds to decrease SGK3 expression was evaluated in
HEK293 cells (Figure 2C). We found that the optimal linker
length was four PEG units (13 atoms), with DAT6 displaying
signiﬁcant improvements both in terms of potency and the
amount of reduction of SGK3 observed compared to the original
DAT1 (Figure 2C). We then changed the composition of the
linkers for more lipophilic alkylic moieties of 13 (DAT8) and 16
atoms (DAT9,10), and for this set of compounds we also
conjugated the inhibitor 290-R (DAT11,12; Figure 2A). The
best compound was DAT8, which we have renamed SGK3-
PROTAC1 (Figure 2D). SGK3-PROTAC1 possesses three
oxygen atoms in the linker motif, the same number as DAT1, but
one less than DAT6 (Figure 2A). At a concentration of 0.1 μM,
SGK3-PROTAC1 reduced SGK3 levels by 65% without
eﬀecting SGK1, SGK2, or S6K1 (Figure 2D). At higher
concentrations of 1−10 μM, moderate degradation of S6K1
was also observed. SGK3-PROTAC1-mediated degradation of
SGK3 was prevented by the neddylation inhibitor MLN4924 as
well as the MG132 proteasome inhibitor (Figure S2). In
biochemical assays, SGK3-PROTAC1 inhibited SGK3 with an
IC50 of 300 nM and S6K1 with an IC50 of 1800 nM (Table 2).
Table 1. IC50 Values and Degradation Eﬃciency of SGK
Inhibitors and First Generation PROTACsa
SGK3 IC50
(nM)
SGK1 IC50
(nM)
S6K1 IC50
(nM)
SGK3 degradation
eﬃciency
290-R 35 19 10
308-R 5 10 1
DAT1 440 1600 160 +
DAT2 190 400 180 −
DAT3 640 1000 240 −
DAT4 540 600 190 −
aThe structures of the inhibitors are shown in Figure 1A. For
degradation eﬃciency, “−” = no degradation and “+” = >50%
degradation at 10 μM. Note, IC50 measurements were not
undertaken in the presence of VHL.
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As before, little correlation was observed between compound
IC50 and degradation eﬃciency. The IC50 of SGK3-PROTAC1
was similar to that of DAT1 (300 from 440 nM), whereas the
IC50 against S6K1 increased approximately 10-fold (0.16 μM to
1.8 μM). The speciﬁcity of SGK3-PROTAC1 at 1 μM was
assessed in a panel of 140 kinases. This revealed a surprising
increase in speciﬁcity over the original 308-R compound, with
SGK1 and S6K1 the only kinases most potently inhibited by this
compound in vitro (Table S1).
Characterization of SGK3-PROTAC1. To generate a
control compound for SGK3-PROTAC1 that would bind and
inhibit SGK3, but not induce recruitment of the CUL2-VHL E3
ligase complex, we synthesized a version of SGK3-PROTAC1
termed cisSGK3-PROTAC1 that contains a hydroxyl epimer of
the VH032 moiety (Figure 2B). Previous work has shown that
this epimer ablates binding to VHL.20,21,35 As expected, in
biochemical assays, cisSGK3-PROTAC1 inhibited our panel of
kinases similarly to SGK3-PROTAC1 (Table S1). We also
Figure 2.Design and cellular evaluation of second and third generation SGKPROTACs. (A) Chemical structure of compounds DAT5−12, expanding
upon DAT1. (B) Chemical structure of cisSGK3-PROTAC1. (C) HEK293 cells were treated for 48 h with increasing concentrations of each
PROTAC compound from 1 nM to 10 μM. Cell lysates were subjected to immunoblot analysis with the indicated antibodies, and SGK3 protein levels
quantiﬁed in Image Studio Lite software. (D) HEK293 cells were treated for 48 h with increasing concentrations of each PROTAC compound from 1
nM to 10 μM. Cell lysates were subjected to immunoblot analysis with the indicated antibodies, and SGK3 and S6K1 protein levels were quantiﬁed in
Image Studio Lite software.
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undertook IC50 measurements of the cisSGK3-PROTAC1
against SGK3, SGK1, and S6K1 and found that values were very
similar to SGK3-PROTAC1 (Table 2). Cellular degradation
assays conﬁrmed that cisSGK3-PROTAC1 failed to induce
degradation of SGK3 even at concentrations of up to 3 μM
under conditions in which 0.1 μM SGK3-PROTAC1 markedly
reduced SGK3 expression (Figure 3A). At doses of up to 1 μM
SGK3-PROTAC1, no degradation of S6K1 was observed.
To study the impact of SGK3-PROTAC1 on phosphorylation
of a physiological substrate, we monitored phosphorylation of
NDRG1 at Thr346.37 This site is also phosphorylated by Akt;
therefore we treated cells with increasing doses of SGK3-
PROTAC1 and cisSGK3-PROTAC1 for 8 h, with the addition
of an Akt inhibitor (3 μMAZD5363) 1 h before lysis, to remove
the impact of Akt phosphorylation of NDRG1. Concentrations
of 0.1 μM SGK3-PROTAC1 reduced NDRG1 phosphorylation
under conditions where cisSGK3-PROTAC1 had no eﬀect
(Figure 3A). Concentrations of cisSGK3-PROTAC1 of above 1
μM were required to lower NDRG1 phosphorylation. Under
basal conditions with no inhibition of Akt, targeting SGK3 with
either 0.3 μM SGK3-PROTAC1 or conventional SGK kinase
inhibitors (1 μM14H or 1 μM308-R) for 8 h hadminimal eﬀect
on pNDRG1 phosphorylation (Figure 3B). In the presence of
the Akt inhibitor (3 μM AZD5363), treatment with 0.3 μM
SGK3-PROTAC1 or 1 μM 14H or 1 μM 308-R markedly
suppressed NDRG1 phosphorylation (Figure 3B). This is
consistent with previous work in HEK293 cells showing that
inhibition of both Akt and SGK3 is required to block NDRG1
phosphorylation.8,37
A time course analysis of 0.3 μM SGK3-PROTAC1 revealed
50% degradation within 2 h, with maximum degradation after 8
h (Figure 3C). This degradation is also reversible, as washout of
SGK3-PROTAC1 after 24 h of treatment resulted in increased
SGK3 expression after 1 h, with protein levels returning to
normal levels after 10 h (Figure 3D).
We also examined the impact of SGK3-PROTAC1 and
cisSGK3-PROTAC1 in two SGK3 dependent breast cancer cell
lines, CAMA-1 (Figure 3E) and ZR-75-1 (Figure 3F).12 In these
cells, concentrations of >0.1 μM SGK3-PROTAC1 induced
degradation of SGK3, but not SGK1 or S6K1. cisSGK3-
PROTAC1 had no impact. To conﬁrm that SGK3-PROTAC1
does not induce degradation of endogenous SGK1, we studied a
breast cancer cell line termed JIMT1 that has been shown
previously to possess high levels of endogenous SGK1.37 In
these cells, concentrations of up to 3 μM SGK3-PROTAC1
failed to induce degradation of SGK1, under conditions where
SGK3 expression was reduced (Figure 3G).
Striking Speciﬁcity of SGK3-PROTAC1. To establish the
speciﬁcity of SGK3-PROTAC1 employing an unbiased
approach, we performed quantitative Tandem−Mass−Tag
(TMT)-labeled global proteomic analysis of HEK293 cells
treated in the presence or absence of 0.3 μM SGK3-PROTAC1
compared to either 0.3 μMcisSGK3-PROTAC1 or DMSO for 8
h. Experiments were undertaken in triplicate, and analysis in
Proteome Discoverer v2.2 using the Mascot search engine
allowed relative quantiﬁcation of 8766 proteins. This analysis
revealed that SGK3-PROTAC1 was remarkably selective with
only SGK3 expression being signiﬁcantly reduced (p value
<10−3; Figure 4 and Table S2).
Eﬀect of SGK3-PROTAC1 on SGK3-Dependent
mTORC1 Activation. Previous work has demonstrated that
prolonged treatment of breast cancer cell lines such as CAMA-1
and ZR-75-1 with PI3K or Akt inhibitors resulted in
upregulation of SGK3, leading to the activation of mTORC1
signaling, mediated by SGK3 phosphorylating TSC2 at the same
sites as Akt.12 We therefore aimed to investigate the eﬀect that
degradation of SGK3 would have on this resistance pathway and
whether SGK3-PROTAC1 treatment could reverse inhibitor
resistance. To investigate the eﬀect of SGK3-PROTAC1 under
these conditions, we treated CAMA-1 (Figure 5A,C) or ZR-75-1
(Figure 5B,D) for 5 days with either a class 1A PI3K inhibitor
(GDC0941 1 μM;38 Figure 5A,B) or an Akt inhibitor
(AZD5363, 1 μM;39 Figure 5C,D). These cells were treated
with SGK3-PROTAC1 or cisSGK3-PROTAC1 (0.3 μM) for
either 5 days in combination with the inhibitors or 8 h before
lysis. SGK3-PROTAC1 substantially reduced SGK3 expression
in both the CAMA-1 and ZR-75-1 cells. Consistent with SGK3-
PROTAC1 blocking mTORC1 activation, we found that it also
suppressed mTORC1-mediated phosphorylation of S6K1 at
Thr389, resulting in a moderate reduction in S6 protein
phosphorylation. In contrast, cisSGK3-PROTAC1 had no
signiﬁcant eﬀect on SGK3 protein level or phosphorylation of
TSC2, S6K1, or S6 protein. Moreover, we also observed that, in
both CAMA-1 and ZR-75-1 cells, SGK3-PROTAC1 inhibited
mTORC1 signaling to a greater extent than an SGK inhibitor
that does not induce degradation of SGK3 (14H 1 μM;13 Figure
5).
Eﬀect of SGK3-PROTAC1 on Proliferation of CAMA-1
and ZR-75-1 Cells Treated with PI3K-Akt Pathway
Inhibitors. Given the impact of SGK3-PROTAC1 treatment
on Akt-independent mTORC1 activation, we expected to
observe a similar eﬀect of SGK3 degradation on cell proliferation
in the context of PI3K-Akt pathway inhibitors. We therefore
studied the eﬀect that SGK3-PROTAC1 and cisSGK3-
PROTAC1 had on the growth of CAMA-1 (Figure 6A,C) or
ZR-75-1 (Figure 6B,D) cells in the absence or presence of the
class 1A PI3K inhibitor (GDC0941, 1 μM; Figure 6A,B) or Akt
inhibitor (AZD5363, 1 μM; Figure 6C,D). Treatment of
CAMA-1 or ZR-75-1 cells with SGK3-PROTAC1 alone had
no eﬀect on growth (Figure S3), consistent with previous work
undertaken with high doses of conventional SGK inhibitors.12,40
As expected, treatment with GDC0941 or AZD5363 substan-
tially reduced growth of these cells (Figure 6). Including SGK3-
Table 2. IC50 Values and Degradation Eﬃciency of Second
Generation of SGK PROTACsa
SGK3
IC50
(μM)
SGK1
IC50
(μM)
S6K1
IC50
(μM)
SGK3
degradation
eﬃciency
DAT1 0.44 1.6 0.16 +
DAT5 >10 >10 >10 +
DAT6 >10 >10 >10 ++
DAT7 >10 >10 >10 ++
DAT8 (SGK3-
PROTAC1)
0.3 0.22 1.8 ++++
cisSGK3-
PROTAC1
0.6 1.4 1.7 −
DAT9 1.79 8.99 4.53 ++
DAT10 >10 >10 >10 ++
DAT11 0.73 1.34 1.80 +++
DAT12 >10 >10 >10 ++
aThe structures of the inhibitors are shown in Figure 2A. “−” = no
degradation, “+” = >50% degradation at 10 μM, “++” = >50%
degradation at 1 μM, “+++” = >50% degradation at 0.1 μM, “++++” =
>60% degradation at 0.1 μM. Note, IC50 measurements were not
undertaken in the presence of VHL.
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PROTAC1 (0.3 μM) further reduced the growth of these cells
under conditions where cisSGK3-PROTAC1 (0.3 μM) had a
minimal eﬀect (Figure 6). We also studied the eﬀect of the
conventional SGK3 inhibitor (14H, 3 μM) on the growth
curves, in order to compare the eﬀects of degradation and kinase
inhibition. As reported previously,12 treatment with 14H further
suppressed cell growth in the context of PI3K class I or Akt
inhibition. In the presence of the PI3K inhibitor (GDC0941 1
μM), SGK3-PROTAC1 (0.3 μM) inhibited cell growth to a
greater extent than treatment with 14H (3 μM; Figure 6A,B).
Figure 3.Characterization of cellular activities of SGK3-PROTAC1 and cisSGK3-PROTAC1. (A)HEK293 cells were ﬁrst treated for 8 h with 0.03−3
μMSGK3-PROTAC1 and cisSGK3-PROTAC1. One hour before lysis, cells were treated with 3 μMAZD5363. Lysates were subjected to immunoblot
analysis with the indicated antibodies. (B) HEK293 cells were treated in the presence or absence of AZD5363 (3 μM), with SGK3-PROTAC1 (0.3
μM), cisSGK3-PROTAC1 (0.3 μM), 14H (1 μM), or 308-R (1 μM) for 8 h prior to lysis. Lysates were subjected to immunoblot analysis with the
indicated antibodies. (C) HEK293 cells were treated for up to 48 h with SGK3-PROTAC1 (0.3 μM), and lysates were analyzed by immunoblot
analysis using the indicated antibodies. (D)HEK293 cells were treated for 24 h with SGK3-PROTAC1. Cells were washed three times with DMEM to
wash out the compound, and recovery of SGK3 expression protein was analyzed by immunoblot analysis. (E−G)As in A except that CAMA-1 (E), ZR-
75-1 (F), and JIMT-1 (G) cells were employed rather than HEK293 cells.
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When combined with the Akt inhibitor (AZD5363 1 μM), 14H
(3 μM) and SGK3-PROTAC1 (0.3 μM) suppressed growth to a
similar extent (Figure 6C,D).
■ CONCLUSION
We describe the design and elaboration of a potent, highly
speciﬁc PROTAC targeted against the SGK3 protein kinase.
SGK3-PROTAC1 induced potent degradation within 2 h, with a
DC50 below 100 nM. Quantitative mass spectrometry revealed
degradation of SGK3 to be highly selective, with SGK3 being the
most downregulated protein. It is particularly interesting that
SGK3-PROTAC1 was revealed to be remarkably speciﬁc for
SGK3 and does not degrade the highly related SGK1 and SGK2
isoforms or any other protein in HEK293 cells. This was even
observed in cell lines such as JIMT-1 which express high levels of
SGK1 and relatively low levels of SGK3. Recent studies
attempting to develop isoform speciﬁc chemical inhibitors of
SGK3 have been unsuccessful, due to the high structural
similarity and sequence identity of the SGK1 and SGK3 kinase
domains, in particularly in the ATP binding site.16 This ability to
generate selective isoform speciﬁc degraders has previously been
observed in PROTACs derived from the pan-BET inhibitor
JQ121,24,41 and PROTACs derived from the promiscuous kinase
inhibitor Foretinib42 or TAE-684.43 It has recently been shown
that speciﬁcity and potency of PROTACs can be dictated by the
diﬀerential cooperativity and stability of ternary complexes that
form protein−protein contacts in relatively less conserved
regions outside the width of the active site of the target
protein19,24,44 as well as the geometry/orientation of the
recruited E3 ligase.45 Future work will investigate the extent to
which these molecular recognition features contribute to the
exquisite selectivity of SGK3-PROTAC1 for SGK3 induced
degradation. Measurement of the stability of the ternary
complexes of SGK3 PROTAC compounds with SGK/S6K
isoforms and the VHL E3 ligase would be important to better
understand the potency and speciﬁcity of these PROTACs.44
Furthermore, it would be interesting to explore the eﬀects that
SGK3 PROTAC degraders have on selective SGK3 substrates
such as STX7 and STX12 that have recently been described that
are not phosphorylated by Akt isoforms.46 The ﬁnding that
growth of SGK3 dependent cancer cell lines is suppressed more
eﬃciently by SGK3-PROTAC1 than achieved by the 14H non-
PROTAC inhibitor provides a further example of the beneﬁt of
the PROTAC approach in targeting protein kinase signaling
pathways with greater eﬃcacy and selectivity than can be
achieved with conventional inhibitors. Other examples include
the recent ﬁnding that a BCR-ABL degrader displays more
sustained inhibition of chronic myelogenous leukemia cell
growth than can be achieved by a conventional ABL kinase
inhibitor.28 SGK3-PROTAC1 will be an important addition to
our armory of chemical probes to decipher the biological roles of
the SGK3 signaling pathway including in mediating resistance to
PI3K and Akt inhibitor therapy in cancer.
■ METHODS
Biology. Materials. Triton X-100, EDTA, EGTA, sodium
orthovanadate, sodium glycerophosphate, sodium ﬂuoride, sodium
pyrophosphate, 2-mercaptoethanol, sucrose, benzamidine, Tween 20,
Tris-HCl, and sodium chloride were from Sigma. Tissue culture
reagents, Novex 4−12% Bis−Tris gels, and NuPAGE LDS sample
buﬀer were from Invitrogen.
Cell Culture and Lysis. ZR-75-1, CAMA-1, and JIMT-1 cell lines
were sourced as described previously.39 HEK293 cells were purchased
from the American Tissue Culture Collection and cultured in DMEM
supplemented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine,
100 U/mL penicillin, and 0.1 mg mL−1 streptomycin. The cells were
lysed in a buﬀer containing 50mMTris−HCl (pH 7.5), 1 mMEGTA, 1
mM EDTA, 1% (v/v) Triton X-100, 1 mM sodium orthovanadate, 50
mM NaF, 5 mM sodium pyrophosphate, 0.27 M sucrose, 10 mM
sodium 2-glycerophosphate, 0.2 mM phenylmethylsulfonyl ﬂuoride,
and 1 mM benzamidine. Lysates were clariﬁed by centrifugation at
16 000g for 10 min at 4 °C. Protein concentration was calculated using
the Bradford assay (Thermo Scientiﬁc).
Cell Treatments and Immunoblot. All cell treatments were carried
out as described in ﬁgure legends, to a ﬁnal DMSO concentration of
0.1% (v/v). Lysates were quantiﬁed. Immunoblotting was performed
using standard procedures, described in brief below. Lysate
concentration was quantiﬁed by Bradford Assay, and 10 μg of lysate
was loaded in the LDS sample buﬀer for SDS-PAGE electrophoresis on
Novex 4−12% Bis−Tris gels. Proteins were electrophoretically
transferred onto nitrocellulose membranes (Amersham Protran 0.45
μm NC; GE Healthcare) at 80 V for 80 min on ice in transfer buﬀer.
Transferred membranes were blocked with 5% (w/v) nonfat dry milk
dissolved in TBS-T [20 mM Tris/HCl, pH 7.5, 150 mM NaCl, and
0.1% (v/v) Tween 20] at RT for 30 min, before incubation with the
primary antibody overnight at 4 °C. The signal was produced with near-
infrared secondary antibodies and detected using a Licor Biosciences
Odyssey System, and the signal was quantiﬁed in Image Studio Lite.
Antibodies. The following antibodies were raised in sheep, by the
MRC−PPU Reagents and Services team (https://mrcppureagents.
dundee.ac.uk/) and aﬃnity puriﬁed against the indicated antigens: anti-
SGK3 (S848D, sixth bleed; raised against human SGK3 PX domain
comprising residues 1−130 of SGK3; DU2034), anti-S6K1 (S417B,
second bleed; raised against residues 25−44 of human S6K1:
AGVFDIDLDQPEDAGSEDEL), anti-SGK1 (S062D, third bleed),
anti-NDRG1 (S276B third bleed; raised against full-length human
NDRG1; DU1557), anti-Akt1 (S695B, third bleed; raised against
residues 466−480 of human Akt1: RPHFPQFSYSASGTA).
Anti-GAPDH was from Santa-Cruz (sc-32233). Antiphospho-Akt
Ser473 (#9271), antiphospho-NDRG1 Thr346 (#5482), antiphospho-
TSC2 Ser939 (#3615), anti-TSC2 (#3612), antiphospho-S6K1
Thr389 (#9205), antiphospho-rpS6 Ser240/244 (#2215), and anti-
Figure 4.TMTproteomic analysis of HEK293 cells treated with SGK3-
PROTAC1. (A) Cells were treated with DMSO (control), SGK3-
PROTAC1 (0.3 μM), or cisSGK3-PROTAC1 (0.3 μM) for 8 h and
lysed. Lysates were subjected to immunoblot analysis with the indicated
antibodies. (B) Lysates were examined by quantitative proteomics.
Volcano plot demonstrating global proteomic changes induced by
SGK3-PROTAC1 treatment versus cisSGK3-PROTAC1 in HEK23
cells.
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rpS6 (#2217) antibodies were purchased from Cell Signaling
Technology. Total anti-SGK antibody was from Sigma (#5188).
Secondary antibodies coupled to IRDye680LT or IRDye800CW
were obtained from Licor Biosciences. Secondary antibodies coupled to
horseradish peroxidase (HRP) were obtained from Thermo Scientiﬁc.
Secondary antibodies coupled to Alexa Fluor 488 and Alexa Fluor 594
were obtained from Thermo Scientiﬁc.
Protein Kinase Proﬁling. Protein kinase proﬁling against a Dundee
panel of 140 protein kinases was undertaken at the International Centre
for Protein Kinase Proﬁling. The result for each kinase was presented as
a mean kinase activity of the reaction taken in triplicate relative to a
control sample treated with DMSO. Assay conditions and abbreviations
are available at http://www.kinase-screen.mrc.ac.uk.
IC50 determination was performed at the MRC PPU International
Centre for Protein Kinase Proﬁling, according to the protocol
previously described47,48
Determination Cell Growth in Vitro. For growth assays, ZR-75-1
cells were seeded in 96-well plates at a density of 6000 cells/well and left
to adhere overnight. Cells were then treated with compounds as
described in the ﬁgure legends and imaged every 4 h on the Incucyte S3
(Essen Bioscience) for up to 4 weeks to give a measure of cell
conﬂuency. Media were refreshed every 4−5 days.
Figure 5. SGK3-PROTAC1-mediated degradation of SGK3 inhibits Akt-independent activation of mTORC1 in cancer cell lines treated with Akt or
PI3K inhibitors. CAMA-1 (A, C) or ZR-75-1 (B, D) were treated for 5 days with 1 μMGDC0941 (A, B) or 1 μMAZD5363 (C, D). Cells were treated
with the compounds indicated for either 5 days or 8 h before lysis; cells were treated with the compounds indicated. Cell lysates were subject to
immunoblot analysis with the indicated antibodies.
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Supplementary Methods. Full chemistry and mass spectrometry
methods are provided in the Supporting Information
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